Gartner, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Gartner provides Research, Conferences and Consulting services. Amounts below are in U.S. dollars; financial statement figures are unaudited.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $1.409 billion | $1.332 billion | $4.321 billion | $3.971 billion |
| Operating income | $244.4 million | $253.4 million | $935.5 million | $767.8 million |
| Net income | $180.0 million | $173.5 million | $673.8 million | $551.0 million |
| Diluted EPS | $2.26 | $2.17 | $8.44 | $6.77 |
| Cash from operations | Not separately stated for the quarter | Not separately stated for the quarter | $931.4 million | $898.3 million |
| Capital expenditures | Not separately stated for the quarter | Not separately stated for the quarter | $75.1 million | $70.5 million |
Q3 revenue grew 6% year over year (5% excluding foreign-exchange effects); nine-month revenue grew 9% reported (10% excluding foreign exchange). Q3 operating margin was approximately 17.3%, versus 19.0%; net margin was approximately 12.8%, versus 13.0%. Nine-month operating income included a $135.4 million pretax gain on the TalentNeuron sale; excluding that gain, operating income was approximately $800.1 million.
Nine-month operating cash flow less capital expenditures was approximately $856.3 million, compared with $827.9 million in 2022. Cash and cash equivalents were $1.249 billion at September 30, 2023. Total debt principal was $2.482 billion, with a net carrying value of $2.460 billion; cash exceeded debt carrying value by approximately $1.21 billion. The company also had about $1.0 billion of available revolver capacity. Deferred revenue, a significant current liability reflecting advance customer billings, was $2.395 billion.
Segments and changes versus prior periods
- Research: Q3 revenue rose 6% to $1.219 billion; nine-month revenue rose 6% to $3.644 billion. Q3 segment gross contribution margin declined to 73% from 74%. Contract value was $4.7 billion, up 8% on a foreign-exchange-neutral basis. Client and wallet retention declined year over year in both Global Technology Sales and Global Business Sales.
- Conferences: Q3 revenue fell 26% to $57.2 million, largely because fewer destination conferences occurred in the quarter as some events were held earlier in 2023. Nine-month revenue increased 45% to $290.7 million, reflecting the return to in-person events. Q3 gross contribution margin was 36%, down from 52%.
- Consulting: Q3 revenue rose 24% to $132.8 million; nine-month revenue rose 12% to $386.3 million. Q3 backlog increased 15% to $180.4 million on a foreign-exchange-neutral basis. Utilization declined to 64% from 66% in Q3 and to 65% from 70% year to date.
Consolidated Q3 operating income declined 4% as service and product-development costs and selling, general and administrative expenses grew faster than revenue. Nine-month operating income and EPS benefited materially from the TalentNeuron divestiture gain. Q3 net income increased 4%; nine-month net income increased 22%.
Liquidity, capital allocation and unusual items
- Nine-month operating cash flow increased to $931.4 million from $898.3 million. Cash flows benefited from stronger collections; the company cited increased income-tax payments as a partial offset.
- Investing activities provided $77.1 million, including $156.1 million of cash proceeds from the TalentNeuron sale. Financing activities used $434.0 million, including $447.7 million for share repurchases.
- Debt principal was $2.482 billion, including $276.8 million of term-loan borrowings. A $350 million interest-rate swap effectively fixes the base rate on variable-rate borrowings. The company reported compliance with credit-facility financial covenants.
- At September 30, $610.8 million remained under the existing repurchase authorization. On October 31, the board authorized an additional $500 million of repurchases; approximately $500 million remained under the prior authorization at October month-end.
- Other notable items included a $3.1 million gain from 2020 event-cancellation insurance proceeds and $19.0 million of nine-month impairment charges, primarily for office lease-related assets no longer expected to be used.
Outlook, commentary and risks
The filing provides no specific revenue or earnings guidance. Management said it believes available cash and revolver capacity are adequate for anticipated needs over the next twelve months and foreseeable future. It cautioned that results for the quarter may not indicate results for the remainder of 2023 or beyond. Consulting contract-optimization revenue may vary significantly; conference revenue is affected by event timing, including the fourth-quarter Symposium/Xpo series.
Management noted that inflation had not materially affected operations or results to date, but warned that personnel-cost inflation might not be fully offset by price increases. Risks identified include macroeconomic and geopolitical conditions, customer retention and contract growth, competition, talent recruitment and retention, conference timing, foreign-exchange movements, cybersecurity, debt service, tax matters and execution of strategic initiatives. The company reported no material changes to the risk factors in its 2022 Form 10-K. It stated that ordinary-course legal matters were not expected to have a material effect beyond amounts accrued. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- How much underlying nine-month growth and profitability remain after excluding the $135.4 million TalentNeuron gain and other unusual items.
- Whether Research contract-value growth can continue as client and wallet retention rates have weakened.
- Whether Q3 Conferences weakness was principally event-calendar timing and how the fourth-quarter event season performs.
- Whether Consulting revenue growth is sustainable given lower utilization and the variable nature of contract-optimization revenue.
- How continued share repurchases affect liquidity, share count and leverage, and whether planned repurchases proceed under the new authorization.
- Potential impacts from office-lease impairments, tax uncertainties, foreign-exchange exposure and the company’s debt obligations.